Clover Health Investments (CLOV) Expected to Announce Earnings on Wednesday

Clover Health Investments (NASDAQ:CLOV) is anticipated to announce its Q2 2026 results after the market closes on Wednesday, August 5th. Analysts expect the company to announce earnings of $0.05 per share and revenue of $728.2660 million for the quarter. Parties can check the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Wednesday, August 5, 2026 at 5:00 PM ET.

Clover Health Investments (NASDAQ:CLOV) last released its quarterly earnings results on Wednesday, May 6th. The company reported $0.05 EPS for the quarter, missing analysts’ consensus estimates of $0.07 by ($0.02). The business had revenue of $749.19 million for the quarter, compared to the consensus estimate of $714.89 million. Clover Health Investments had a negative return on equity of 16.52% and a negative net margin of 2.58%.

Clover Health Investments Price Performance

NASDAQ CLOV opened at $4.34 on Wednesday. The stock’s 50 day simple moving average is $4.54 and its 200 day simple moving average is $3.07. Clover Health Investments has a one year low of $1.58 and a one year high of $5.59. The firm has a market cap of $2.29 billion, a PE ratio of -36.16 and a beta of 2.41.

Analyst Ratings Changes

A number of research firms have commented on CLOV. Wall Street Zen raised Clover Health Investments from a “hold” rating to a “buy” rating in a research note on Saturday, June 6th. Weiss Ratings restated a “sell (d-)” rating on shares of Clover Health Investments in a research note on Wednesday, June 24th. Canaccord Genuity Group lifted their price target on Clover Health Investments from $4.20 to $5.50 and gave the company a “buy” rating in a report on Tuesday, July 21st. Finally, UBS Group upped their price target on shares of Clover Health Investments from $2.75 to $4.75 and gave the stock a “neutral” rating in a research report on Thursday, June 11th. One equities research analyst has rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $4.25.

Insiders Place Their Bets

In other Clover Health Investments news, CEO Brady Patrick Priest sold 98,039 shares of the company’s stock in a transaction on Wednesday, May 13th. The stock was sold at an average price of $3.52, for a total transaction of $345,097.28. Following the transaction, the chief executive officer owned 2,040,222 shares of the company’s stock, valued at approximately $7,181,581.44. This represents a 4.58% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Joseph Frank Oldakowski sold 12,102 shares of the company’s stock in a transaction on Tuesday, June 16th. The stock was sold at an average price of $4.86, for a total value of $58,815.72. Following the transaction, the vice president directly owned 299,067 shares in the company, valued at approximately $1,453,465.62. This represents a 3.89% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 715,884 shares of company stock valued at $3,202,372 over the last quarter. Company insiders own 23.51% of the company’s stock.

Institutional Investors Weigh In On Clover Health Investments

A number of institutional investors and hedge funds have recently made changes to their positions in CLOV. Virtu Financial LLC acquired a new position in shares of Clover Health Investments during the third quarter valued at $101,000. Canada Pension Plan Investment Board bought a new position in Clover Health Investments in the second quarter valued at about $88,000. Mackenzie Financial Corp acquired a new stake in Clover Health Investments in the third quarter worth about $80,000. Cibc World Markets Corp bought a new stake in Clover Health Investments during the 4th quarter worth about $64,000. Finally, Tower Research Capital LLC TRC lifted its position in Clover Health Investments by 179.9% during the 2nd quarter. Tower Research Capital LLC TRC now owns 22,916 shares of the company’s stock valued at $64,000 after purchasing an additional 14,730 shares during the period. Institutional investors own 19.77% of the company’s stock.

About Clover Health Investments

Clover Health Investments is a technology-driven healthcare company specializing in Medicare Advantage plans for senior populations. The company combines insurance coverage with a proprietary software platform to improve care coordination, outcomes tracking and cost management. By leveraging data analytics, Clover Health aims to deliver personalized care pathways and preventive interventions for its members.

At the core of Clover’s offering is its Clover Assistant platform, which aggregates clinical and claims data from multiple sources to create real-time insights for physicians and care teams.